Last week’s FY results were ahead of expectations, and the clinical development of lead programmes is progressing on track. In this note we detail the hRPC platform, ahead of the expected top-line Phase IIa readout in October on all 12 patients in the Retinitis Pigmentosa (RP) trial. In our view, ReNeuron’s hRPC platform is a world-leading endeavour in the treatment of RP. We look forward to the data release with anticipation, and reiterate our positive stance with an intrinsic value of 332p/sha ....
19 Jul 2019
Exciting times ahead: hRPC read-out in October
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Exciting times ahead: hRPC read-out in October
ReNeuron Group plc (RENE:LON) | 0 0 0.0% | Mkt Cap: 1.74m
- Published:
19 Jul 2019 -
Author:
Jens Lindqvist -
Pages:
3
Last week’s FY results were ahead of expectations, and the clinical development of lead programmes is progressing on track. In this note we detail the hRPC platform, ahead of the expected top-line Phase IIa readout in October on all 12 patients in the Retinitis Pigmentosa (RP) trial. In our view, ReNeuron’s hRPC platform is a world-leading endeavour in the treatment of RP. We look forward to the data release with anticipation, and reiterate our positive stance with an intrinsic value of 332p/sha ....